FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy

On August 5, 2016, the U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA injection, Merck Sharp & Dohme Corp., Kenilworth, NJ) for treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncologist
Hoofdauteurs: Larkins, Erin, Blumenthal, Gideon M., Yuan, Weishi, He, Kun, Sridhara, Rajeshwari, Subramaniam, Sriram, Zhao, Hong, Liu, Chao, Yu, Jingyu, Goldberg, Kirsten B., McKee, Amy E., Keegan, Patricia, Pazdur, Richard
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: AlphaMed Press 2017
Onderwerpen:
Regulatory Issues: FDA
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5507654/
https://ncbi.nlm.nih.gov/pubmed/28533473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0496
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items